Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Fabrizia Mariotti (Parma, Italy), Fabrizia Mariotti, Sara Collarini, Stefano Vezzoli, Daniela Acerbi, Maxim Kots, Piotr Kuna. Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients. Eur Respir J 2016; 48: Suppl. 60, 4064

Member's Comments

No comment yet.

Related content which might interest you: 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Pharmacokinetics of tiotropium in asthma patients from three paediatric clinical trials Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Safety and tolerability of acute dosing of beta-blockers in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients Source: International Congress 2014 – Asthma and COPD management Year: 2014 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Effects of aclidinium bromide/formoterol fumarate fixed-dose combination on health status in COPD Source: International Congress 2014 – COPD markers Year: 2014 Safety of tiotropium in renally impaired patients Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily QVA149 has a good safety profile in patients with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013